In a bold move against a backdrop of federal uncertainty, MapLight Therapeutics has gone public, raising $251 million in its initial public offering (IPO) — a rare listing to pierce through the silence of a government shutdown that has largely stalled Wall Street’s IPO engine.

The California-based biotechnology company sold 14.75 million shares at $17 each, beginning trade on the Nasdaq Monday under the ticker MPLT, according to its statement. The offering, one of the few to cross the finish line during the shutdown, signals investor confidence in the company’s mission to transform treatment for neuropsychiatric and central nervous system disorders.

A Rare Market Entry During a Shutdown

While Washington remains gridlocked, MapLight is writing its own narrative of resilience. Its IPO was guided by Cooley LLP, while underwriters were advised by Latham & Watkins LLP — firms with deep roots in biotech and life sciences deals.

The IPO is paired with a concurrent private sale of roughly 476,700 shares at the same price, adding an extra $7.9 million to the company’s coffers for a total of $258.9 million raised. At pricing, MapLight commands a valuation of $704 million.

Pioneering Treatments for the Mind

MapLight’s focus is both ambitious and timely. The company is developing therapies for neuropsychiatric and central nervous system disorders, including a lead drug candidate aimed at schizophrenia and Alzheimer’s disease psychosis.

In July, MapLight announced it had raised $372.5 million in an oversubscribed Series D financing round, showing strong investor appetite even before its market debut.

According to its SEC filing, the biotech plans to channel IPO proceeds into clinical development, funding its lead and pipeline therapies through Phase 2 trials. Additional funds will go toward working capital, corporate operations, and potential acquisitions or in-licensing of complementary technologies.

Heavyweight Investors Back the Vision

Backing the IPO are several powerhouse investors, including Novo Holdings, nonprofit Catalyst4, and venture capital firm Forbion Growth. Cornerstone investor T. Rowe Price also signaled confidence, committing to purchase $40 million worth of shares.

Despite the chilling effect of the ongoing shutdown on the U.S. Securities and Exchange Commission’s ability to review filings, MapLight managed to navigate the regulatory maze and make its market debut — a testament to preparation and timing.

Legal Teams Behind the Deal

MapLight’s IPO was steered by Cooley partners Christian Plaza, Mark Ballantyne, Madison Jones, Katherine Denby, Michael Tuscan, Alessandra Murata, Carly Mitchell, Sonia Nath, Phil Mitchell, and Michael Egan.

Representing the underwriters, Latham & Watkins LLP’s team included Nathan Ajiashvili and Matthew Bush, ensuring smooth sailing through turbulent market conditions.

With this milestone, MapLight Therapeutics shines a light of optimism across a dim IPO landscape — its $251 million debut serving as both a financial victory and a symbol of biotech endurance amid government paralysis.